Ayunova Pharmaceutical LLP

Product Name:

Adalimumab Pre-Filled Syringe (PFS) 40 mg / 0.8 ml

Description:

Adalimumab is a recombinant human monoclonal antibody (anti-TNF-α) used in the treatment of various autoimmune and inflammatory disorders. It works by selectively inhibiting tumor necrosis factor-alpha (TNF-α), a key mediator of inflammation. The pre-filled syringe (PFS) formulation ensures accurate dosing, ease of administration, and improved patient compliance, making it suitable for hospital, clinic, and supervised home use.

Composition (per 0.8 ml PFS):

• Adalimumab: 40 mg

• Excipients: Water for injection, buffering agents, stabilizers, and BP/USP-grade excipients

Each pre-filled syringe delivers a precise dose of 40 mg in 0.8 ml.

Uses / Indications:

• Rheumatoid arthritis

• Ankylosing spondylitis

• Psoriatic arthritis

• Plaque psoriasis

• Crohn’s disease

• Ulcerative colitis

• Juvenile idiopathic arthritis

Dosage and Administration:

• Administered via subcutaneous injection

• Dosage and frequency as prescribed by a physician based on indication and patient response

• Must be used under the supervision of a qualified healthcare professional

Key Features:

• Targeted anti-TNF-α therapy

• Pre-filled syringe for accurate, ready-to-use dosing

• Sterile and BP/USP-compliant formulation

• Improves symptom control and quality of life in chronic inflammatory diseases

Packaging:

• 0.8 ml PFS containing 40 mg Adalimumab

• Supplied in individual blister packs or cartons

Storage Conditions:

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light

• Keep out of reach of children

Product Name:

Etanercept Pre-Filled Syringe (PFS) 50 mg / 1 ml

Description:

Etanercept is a recombinant human tumor necrosis factor (TNF) receptor fusion protein used in the treatment of autoimmune and inflammatory disorders. It works by inhibiting tumor necrosis factor-alpha (TNF-α), a key mediator of inflammation. The pre-filled syringe (PFS) formulation ensures accurate dosing, ease of administration, and improved patient compliance, making it suitable for hospital, clinic, and supervised home use.

Composition (per 1 ml PFS):

• Etanercept: 50 mg

• Excipients: Water for injection, buffering agents, stabilizers, and BP/USP-grade excipients

Each pre-filled syringe delivers a precise dose of 50 mg in 1 ml.

Uses / Indications:

• Rheumatoid arthritis

• Ankylosing spondylitis

• Psoriatic arthritis

• Plaque psoriasis

• Juvenile idiopathic arthritis

Dosage and Administration:

• Administered via subcutaneous injection

• Dosage and frequency as prescribed by a physician based on indication and patient response

• Must be used under the supervision of a qualified healthcare professional

Key Features:

• Targeted anti-TNF-α therapy

• Pre-filled syringe for accurate, ready-to-use dosing

• Sterile and BP/USP-compliant formulation

• Improves symptom control and quality of life in chronic inflammatory diseases

Packaging:

• 1 ml PFS containing 50 mg Etanercept

• Supplied in individual blister packs or cartons

Storage Conditions:

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light

• Keep out of reach of children

Product Name:

Chlorpheniramine + Dexamethasone For Injection BP

Description:

Chlorpheniramine + Dexamethasone For Injection BP is a sterile injectable formulation combining an antihistamine and a corticosteroid. Chlorpheniramine is an H1-antihistamine that helps relieve allergic symptoms, while Dexamethasone is a potent corticosteroid that reduces inflammation and suppresses immune responses. This combination is ideal for rapid management of severe allergic reactions, anaphylaxis, and acute inflammatory conditions.

Composition (per 1 ml):

• Chlorpheniramine Maleate: 10 mg

• Dexamethasone Sodium Phosphate: 4–8 mg

• Excipients: Water for injection, BP/USP-grade stabilizers

Strengths may vary depending on manufacturer specifications.

Uses / Indications:

• Management of severe allergic reactions and anaphylaxis

• Treatment of acute urticaria and angioedema

• Adjunct therapy in asthma exacerbations

• Reduction of inflammation in acute allergic or hypersensitivity reactions

Dosage and Administration:

• Administered via intravenous or intramuscular injection as prescribed by a physician

• Dosage depends on patient age, severity of reaction, and clinical condition

• Must be used under supervision of a qualified healthcare professional

Key Features:

• Combines antihistamine and corticosteroid for rapid relief

• Sterile, pyrogen-free, and BP-compliant formulation

• Provides quick control of severe allergic and inflammatory reactions

• Suitable for hospital, emergency, and clinical use

Packaging:

• 1 ml, 2 ml, 5 ml vials

• Prefilled syringes available on request

Storage Conditions:

• Store at 2–8°C (refrigerated)

• Protect from light

• Keep out of reach of children

Product Name:

Tocilizumab Pre-Filled Syringe (PFS) 162 mg / 0.9 ml

Description:

Tocilizumab is a humanized monoclonal antibody that acts as an interleukin-6 (IL-6) receptor antagonist. It is used to treat various autoimmune and inflammatory conditions by inhibiting IL-6 mediated immune responses. The pre-filled syringe (PFS) formulation ensures accurate dosing, ease of administration, and improved patient compliance. Tocilizumab is commonly indicated for rheumatoid arthritis, juvenile idiopathic arthritis, and cytokine release syndrome associated with CAR-T cell therapy.

Composition (per 0.9 ml PFS):

• Tocilizumab: 162 mg

• Excipients: Water for injection, stabilizers, buffering agents, and BP/USP-grade excipients

Each pre-filled syringe delivers 162 mg in 0.9 ml.

Uses / Indications:

• Rheumatoid arthritis in adults and children

• Systemic juvenile idiopathic arthritis

• Polyarticular juvenile idiopathic arthritis

• Cytokine release syndrome (CRS) associated with CAR-T cell therapy

• Other autoimmune and inflammatory disorders as prescribed by a physician

Dosage and Administration:

• Administered via subcutaneous injection

• Dose and frequency depend on patient weight, condition, and response to therapy

• Must be used under supervision of a qualified healthcare professional

Key Features:

• Monoclonal antibody targeting IL-6 receptors for effective immunomodulation

• Pre-filled syringe for accurate, ready-to-use dosing

• Sterile, pyrogen-free, and BP/USP-compliant formulation

• Suitable for hospital, clinic, and supervised home use

Packaging:

• 0.9 ml PFS containing 162 mg Tocilizumab

• Supplied in individual blister packs or cartons

Storage Conditions:

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light

• Keep out of reach of children

Product Name

Aceclofenac + Paracetamol Tablets BP – 425 mg

Product Description

Aceclofenac + Paracetamol Tablets BP is a combination analgesic and anti-inflammatory medication used for relief of pain and inflammation in musculoskeletal disorders.

• Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis, reducing inflammation, pain, and swelling.

• Paracetamol (Acetaminophen) provides analgesic and antipyretic effects, enhancing pain relief and reducing fever.

This combination is widely prescribed for joint pain, musculoskeletal disorders, and post-operative pain, providing rapid and effective symptom relief.

Composition

Each tablet contains:

• Aceclofenac BP – 100 mg

• Paracetamol BP – 325 mg

• Excipients: q.s. to make a tablet

Major Indications / Uses Primary Indications

• Osteoarthritis and rheumatoid arthritis

• Acute musculoskeletal pain and strains

• Post-operative pain and inflammation

Other Uses

• Dental pain

• Migraine and tension headaches

• Menstrual pain (dysmenorrhea)

Dosage & Administration

• Route: Oral

• Typical Adult Dose: 1 tablet twice daily, or as prescribed by a physician

• Pediatric Dose: Only if recommended by a doctor, based on age and weight

• Monitoring: Gastrointestinal tolerance, renal and liver function during prolonged therapy

⚠ Take after food to reduce gastrointestinal irritation
⚠ Use under medical supervision in patients with cardiovascular, renal, or hepatic conditions

Packaging Details

• Strip packaging: 10 × 10 tablets

• Bottle packaging: 100 tablets per bottle

• Hospital and bulk packaging available

Storage Conditions

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Product Description

Enbrel® 25 mg Injection contains Etanercept, a recombinant human tumor necrosis factor (TNF-α) receptor fusion protein. It is a biologic disease-modifying antirheumatic drug (bDMARD) used to reduce inflammation and halt disease progression in various autoimmune and inflammatory disorders. Enbrel works by neutralizing TNF-α, a key cytokine involved in chronic inflammation.

Composition

Each vial / prefilled syringe contains:

• Etanercept – 25 mg

• Sterile excipients – q.s.

Uses / Indications

Enbrel 25 mg Injection is indicated for the treatment of:

• Rheumatoid arthritis (moderate to severe)

• Juvenile idiopathic arthritis (JIA)

• Psoriatic arthritis

• Ankylosing spondylitis

• Plaque psoriasis (moderate to severe)

Dosage & Administration

• Administered by subcutaneous injection

• Dosage and frequency as prescribed by a rheumatologist or specialist

• Can be self-administered after proper training

• Rotate injection sites to reduce local reactions

Storage Instructions

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light

• Allow to reach room temperature before injection

Packaging

• Single-use vial or prefilled syringe

• Strength: 25 mg

Sulfasalazine Delayed Release Tablets USP 1000 mg Product Description

Sulfasalazine Delayed Release Tablets USP 1000 mg is an oral anti-inflammatory medication used for the management of inflammatory bowel disease and rheumatoid arthritis. The delayed-release formulation ensures that the active ingredient is released in the intestines rather than the stomach, minimizing gastrointestinal irritation. This medicine should be used under the supervision of a qualified healthcare professional.

Composition

• Active Ingredient:
  Sulfasalazine – 1000 mg

• Excipients:
  q.s.

• Dosage Form:
  Delayed-release tablets

Uses / Indications

Sulfasalazine Delayed Release Tablets are indicated for:

• Ulcerative colitis

• Crohn’s disease

• Rheumatoid arthritis (as prescribed by a physician)

(Prescription medicine – use only under medical supervision)

Dosage & Administration

• Dosage as directed by the treating physician

• Tablets should be swallowed whole with water

• Usually taken after meals to reduce gastrointestinal discomfort

• Regular monitoring may be required for long-term therapy

Storage Instructions

• Store below 25°C

• Protect from moisture and direct sunlight

• Keep out of reach of children

Precautions & Warnings

• For prescription use only

• Not recommended during pregnancy or breastfeeding unless prescribed

• Monitor liver, kidney function, and blood counts during prolonged therapy

• Use with caution in patients with sulfa allergy

Packaging Details

• Strip or bottle packing (as available)

• Suitable for hospital and pharmacy supply

Quality Standards

• Manufactured in compliance with USP and GMP guidelines

• Quality tested for safety, purity, and efficacy

Country of Origin

• India

Tofacitinib 5 mg Tablets – JAKURA Product Description

JAKURA Tablets contain Tofacitinib 5 mg, an oral Janus kinase (JAK) inhibitor used in the treatment of autoimmune and inflammatory disorders. Tofacitinib helps control immune system overactivity, thereby reducing inflammation, joint pain, swelling, and disease progression. This medicine is recommended for patients who have not responded adequately to conventional therapies and should be used strictly under medical supervision.

Composition

• Active Ingredient:
  Tofacitinib – 5 mg per tablet

• Excipients:
  q.s.

• Dosage Form:
  Film-coated tablet

• Pharmacopoeial Standard:
  IP

Uses / Indications

Tofacitinib Tablets 5 mg are indicated for:

• Moderate to severe rheumatoid arthritis

• Psoriatic arthritis

• Ulcerative colitis

• Other autoimmune or inflammatory conditions as prescribed by a physician

(Prescription medicine – use only under medical supervision)

Dosage & Administration

• Dosage as prescribed by the treating physician

• Taken orally, with or without food

• Tablets should be swallowed whole with water

• Regular monitoring of blood counts and liver function is advised

Storage Instructions

• Store below 30°C

• Protect from moisture and direct sunlight

• Keep out of reach of children

Precautions & Warnings

• For prescription use only

• Increased risk of serious infections; patient monitoring required

• Not recommended during pregnancy or breastfeeding unless prescribed

• Use with caution in patients with hepatic, renal, or cardiovascular disorders

Packaging Details

• Strip or bottle packing (as available)

• Suitable for hospital, pharmacy, and distributor supply

Quality Standards

• Manufactured in accordance with IP & GMP guidelines

• Quality tested for safety, purity, and efficacy

Country of Origin

• India

Lefvaz – Leflunomide Tablets 10 mg Product Description

Lefvaz Tablets contain Leflunomide 10 mg, a disease-modifying antirheumatic drug (DMARD) used in the treatment of autoimmune and inflammatory conditions. Leflunomide works by inhibiting pyrimidine synthesis, thereby reducing immune system overactivity and inflammation. It helps slow disease progression, relieve joint pain, and improve physical function in patients with rheumatoid arthritis. This medicine should be used under strict medical supervision.

Composition

• Active Ingredient:
  Leflunomide – 10 mg per tablet

• Excipients:
  q.s.

• Dosage Form:
  Film-coated tablets

• Pharmacopoeial Standard:
  IP

Uses / Indications

Lefvaz (Leflunomide) Tablets are indicated for:

• Rheumatoid arthritis (active to moderate-severe)

• Autoimmune inflammatory disorders as prescribed by a physician

(Prescription medicine – use only under medical supervision)

Dosage & Administration

• Dosage as directed by the treating physician

• Taken orally, with or without food

• Tablets should be swallowed whole with water

• Regular monitoring of liver function and blood counts is recommended

Storage Instructions

• Store below 30°C

• Protect from moisture and direct sunlight

• Keep out of reach of children

Sulfasalazine Gastro-Resistant Tablets IP 500 mg Product Description

Sulfasalazine Gastro-Resistant Tablets IP 500 mg is an oral anti-inflammatory medication used in the management of inflammatory bowel disease and rheumatoid arthritis. The gastro-resistant coating ensures that the active ingredient is released in the intestines rather than the stomach, reducing gastrointestinal irritation. This medicine should be used under the supervision of a qualified healthcare professional.

Composition

• Active Ingredient:
  Sulfasalazine – 500 mg

• Excipients:
  q.s.

• Dosage Form:
  Gastro-resistant tablets

Uses / Indications

Sulfasalazine Gastro-Resistant Tablets are indicated for:

• Ulcerative colitis

• Crohn’s disease

• Rheumatoid arthritis (as prescribed by a physician)

(Prescription medicine – use only under medical supervision)

Dosage & Administration

• Dosage as directed by the treating physician

• Tablets should be swallowed whole with water

• Usually taken after meals to reduce gastrointestinal discomfort

• Regular monitoring may be required for long-term therapy

Storage Instructions

• Store below 25°C

• Protect from moisture and direct sunlight

• Keep out of reach of children

Precautions & Warnings

• For prescription use only

• Not recommended during pregnancy or breastfeeding unless prescribed

• Monitor for liver, kidney function, and blood counts during prolonged therapy

• Use with caution in patients with sulfa allergy

Packaging Details

• Strip or bottle packing (as available)

• Suitable for hospital and pharmacy supply

Quality Standards

• Manufactured in compliance with IP and GMP guidelines

• Quality tested for safety, purity, and efficacy

Country of Origin

• India